BACKGROUND: Accurate quantification of total HIV-DNA and residual-viremia by sensitive assays is extremely useful to optimize monitoring of ART-treated patients. OBJECTIVES: To evaluate the performances of two ddPCR-based assays for HIV-DNA and residual-viremia quantification, and the correlations of pre-ART HIV-DNA with plasma HIV-RNA, CD4 + T, CD4/CD8 and virological-success (VS) during first-line ART. STUDY DESIGN: Plasma HIV-RNA, total HIV-DNA, CD4 + T, CD4/CD8 were evaluated at baseline of ART, at VS (viral-load <50copies/ml), and at 6 months after VS (6moVS) in 57 newly-diagnosed HIV-1 infected patients, receiving first-line modern ART. HIV-DNA (log10 copies/106CD4 + T) and residual-viremia (copies/ml) were measured with in-house ddPCR assays. Correlations were assessed by Spearman and Jonckheere-Terpstra tests. RESULTS: HIV-DNA and residual-viremia assays showed a good linear trend between the expected and obtained values (R2 = 0.9913 and 0.9945); lower limits of detection were 32 copies/106CD4 + T and 2 copies/ml, respectively. At baseline, median (IQR) plasma HIV-RNA and HIV-DNA were 4.88(4.28-5.36)log10 copies/ml and 4.00(3.36-4.51) log10 copies/106CD4 + T cells. Residual-viremia was 8(2-26) and 4(2-12) copies/ml at VS and 6moVS. Pre-ART HIV-DNA positively correlated with plasma HIV-RNA at BL (Rho = 0.708, p < 0.001), and with residual-viremia at VS (Rho:0.383,p = 0.002). Notably, higher HIV-DNA correlated with longer time to achieve VS (median[IQR],weeks: 17.8[12.3-29.0] for HIV-DNA ≥4.5 vs. 7.4[4.1-8.7] for HIV-DNA<4.5, p < 0.001). Furthermore, pre-ART HIV-DNA negatively correlated with CD4 + T and CD4/CD8 at baseline, VS and 6moVS. CONCLUSIONS: Our results support the adoption of ddPCR-based assays for both HIV-DNA and residual-viremia quantifications and corroborate that pre-ART HIV-DNA is an excellent indicator in predicting viroimmunological response and VS in patients starting ART.
BACKGROUND: Accurate quantification of total HIV-DNA and residual-viremia by sensitive assays is extremely useful to optimize monitoring of ART-treated patients. OBJECTIVES: To evaluate the performances of two ddPCR-based assays for HIV-DNA and residual-viremia quantification, and the correlations of pre-ART HIV-DNA with plasma HIV-RNA, CD4 + T, CD4/CD8 and virological-success (VS) during first-line ART. STUDY DESIGN: Plasma HIV-RNA, total HIV-DNA, CD4 + T, CD4/CD8 were evaluated at baseline of ART, at VS (viral-load <50copies/ml), and at 6 months after VS (6moVS) in 57 newly-diagnosed HIV-1 infectedpatients, receiving first-line modern ART. HIV-DNA (log10 copies/106CD4 + T) and residual-viremia (copies/ml) were measured with in-house ddPCR assays. Correlations were assessed by Spearman and Jonckheere-Terpstra tests. RESULTS: HIV-DNA and residual-viremia assays showed a good linear trend between the expected and obtained values (R2 = 0.9913 and 0.9945); lower limits of detection were 32 copies/106CD4 + T and 2 copies/ml, respectively. At baseline, median (IQR) plasma HIV-RNA and HIV-DNA were 4.88(4.28-5.36)log10 copies/ml and 4.00(3.36-4.51) log10 copies/106CD4 + T cells. Residual-viremia was 8(2-26) and 4(2-12) copies/ml at VS and 6moVS. Pre-ART HIV-DNA positively correlated with plasma HIV-RNA at BL (Rho = 0.708, p < 0.001), and with residual-viremia at VS (Rho:0.383,p = 0.002). Notably, higher HIV-DNA correlated with longer time to achieve VS (median[IQR],weeks: 17.8[12.3-29.0] for HIV-DNA ≥4.5 vs. 7.4[4.1-8.7] for HIV-DNA<4.5, p < 0.001). Furthermore, pre-ART HIV-DNA negatively correlated with CD4 + T and CD4/CD8 at baseline, VS and 6moVS. CONCLUSIONS: Our results support the adoption of ddPCR-based assays for both HIV-DNA and residual-viremia quantifications and corroborate that pre-ART HIV-DNA is an excellent indicator in predicting viroimmunological response and VS in patients starting ART.
Authors: Yann Le Duff; Kathleen Gärtner; Eloise J Busby; Annalisa Dalzini; Sivapragashini Danaviah; José Luis Jiménez Fuentes; Carlo Giaquinto; Jim F Huggett; Matthew Hurley; Anne-Geneviève Marcellin; María Ángeles Muñoz-Fernández; Denise M O'Sullivan; Deborah Persaud; Laura Powell; Peter Rigsby; Paolo Rossi; Anita de Rossi; Lilly Siems; Theresa Smit; Sarah A Watters; Neil Almond; Eleni Nastouli Journal: Microbiol Spectr Date: 2022-06-06
Authors: Sivaporn Gatechompol; Lu Zheng; Yajing Bao; Anchalee Avihingsanon; Stephen J Kerr; Nagalingeswaran Kumarasamy; James G Hakim; Frank Maldarelli; Robert J Gorelick; Jorden L Welker; Jeffrey D Lifson; Mina C Hosseinipour; Joseph J Eron; Kiat Ruxrungtham Journal: Medicine (Baltimore) Date: 2021-09-03 Impact factor: 1.817
Authors: Elena Bresciani; Nicola Squillace; Valentina Orsini; Roberta Piolini; Laura Rizzi; Laura Molteni; Ramona Meanti; Alessandro Soria; Giuseppe Lapadula; Alessandra Bandera; Andrea Gori; Paolo Bonfanti; Robert John Omeljaniuk; Vittorio Locatelli; Antonio Torsello Journal: Int J Mol Sci Date: 2022-03-23 Impact factor: 5.923
Authors: Héloïse M Delagreverie; Claire Bauduin; Nathalie De Castro; Beatriz Grinsztejn; Marc Chevrier; Fanélie Jouenne; Samia Mourah; Issa Kalidi; Jose Henrique Pilotto; Carlos Brites; Nemora Tregnago Barcellos; Ali Amara; Linda Wittkop; Jean-Michel Molina; Constance Delaugerre Journal: Open Forum Infect Dis Date: 2020-01-11 Impact factor: 3.835